Poseida Therapeutics, Inc.·4

Mar 1, 7:27 PM ET

Warner Brent 4

4 · Poseida Therapeutics, Inc. · Filed Mar 1, 2022

Insider Transaction Report

Form 4
Period: 2022-03-01
Warner Brent
President, Gene Therapy
Transactions
  • Award

    Common Stock

    2022-03-01+307,881307,881 total
  • Award

    Stock Option (Right to Buy)

    2022-03-01+431,034431,034 total
    Exercise: $3.42Exp: 2032-02-29Common Stock (431,034 underlying)
Footnotes (2)
  • [F1]Represents shares issuable upon the vesting of restricted stock units granted pursuant to the Issuer's Inducement Plan. The RSUs are scheduled to vest in four equal annual installments.
  • [F2]12.5% of the shares subject to the stock option will vest and become exercisable on the six-month anniversary of the grant date listed in column 3 above, and the remaining shares will vest in 42 equal monthly installments thereafter.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION